Written question asked by Freddie van Mierlo (Liberal Democrat) on Tuesday, 13 January 2026, in the House of Commons. It was due for an answer on Monday, 19 January 2026 (named day). It was answered by Zubir Ahmed (Labour) on Monday, 19 January 2026 on behalf of the Department of Health and Social Care.
Givinostat
- Question
-
To ask the Secretary of State for Health and Social Care, what discussions has he had to help conclude the dialogue between NHS England and the manufacturer of givinostat as part of the NICE appraisal.
- Answer
-
The Department has had no such discussions. NHS England is responsible for any commercial discussions with companies whose products are undergoing a National Institute for Health and Care Excellence evaluation.
Following discussions in November 2025, NHS England invited the manufacturer, ITF Pharma UK and Ireland, to submit a written proposal to progress a potential commercial agreement in December, with a range of ideas being offered by NHS England that could form the basis of a deal.
NHS England is still awaiting a proposal from the company and has continued to press ITF Pharma on the need to make progress as patients and campaigners deserve certainty on the next steps regarding access to this treatment.
Secondary information
- Type
- Written question
- Reference
- 105612
- Session
- 2024-26
- Related items
- Subjects
- National Institute for Health and Care Excellence Givinostat NHS England
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-02-23 12:26:50 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/105612
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/105612
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2024-26/105612